9 withdrawn, 4 terminated, 2 completed. 14 Phase 2, 12 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Withdrawn 9, Terminated 4, Completed 1 |
| Phase 1 | 12 | Withdrawn 7, Terminated 4, Completed 1 |
Follow yeast-CEA vaccine: new trials by email Literature Review of yeast-CEA vaccine trials Research Report on yeast-CEA vaccine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine Aldoxorubicin Hydrochloride, ALT-803, ETBX-011 - Colorectal Cancer Metastatic, mCRC | Phase 1 / Phase 2 | Terminated | ImmunityBio, Inc. | 2 | 2018-09-28 | 2024-12-11 |
| QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine Leucovorin, 5-Fluorouracil, Aldoxorubicin HCl - Triple Negative Breast Cancer (TNBC) | Phase 2 | Withdrawn | ImmunityBio, Inc. | 2018-09-01 | 2025-02-21 | |
| QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC avelumab, bevacizumab, capecitabine - Colorectal Cancer | Phase 1 / Phase 2 | Withdrawn | ImmunityBio, Inc. | 2018-08-01 | 2025-02-21 | |
| QUILT-3.088: NANT Pancreatic Cancer Vaccine Gemcitabine, Nab-paclitaxel, Aldoxorubicin HCl - Metastatic Pancreatic Cancer | Phase 2 | Withdrawn | ImmunityBio, Inc. | 2018-08-01 | 2025-02-21 | |
| QUILT-3.080: NANT Pancreatic Cancer Vaccine Aldoxorubicin HCl, ALT-803, ETBX-011 - Pancreatic Cancer | Phase 1 / Phase 2 | Terminated | ImmunityBio, Inc. | 3 | 2018-07-17 | 2024-08-27 |
| QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine ETBX-011, GI-4000, haNK for infusion - Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent | Phase 1 / Phase 2 | Withdrawn | ImmunityBio, Inc. | 2018-05-25 | 2021-03-18 | |
| QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy. Aldoxorubicin HCl, N-803, ETBX-011 - Triple Negative Breast Cancer | Phase 1 / Phase 2 | Terminated | ImmunityBio, Inc. | 9 | 2018-03-19 | 2024-08-09 |
| QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors avelumab, Bevacizumab, Capecitabine - Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Withdrawn | ImmunityBio, Inc. | 2018-02-01 | 2025-02-21 | |
| QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed Aldoxorubicin HCl, ETBX-011, ETBX-021 - Squamous Cell Carcinoma | Phase 1 / Phase 2 | Terminated | ImmunityBio, Inc. | 4 | 2018-01-09 | 2024-08-05 |
| QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy avelumab, bevacizumab, capecitabine - Triple Negative Breast Cancer | Phase 1 / Phase 2 | Withdrawn | ImmunityBio, Inc. | 2017-12-01 | 2025-02-21 | |
| QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy Avelumab, Bevacizumab, Capecitabine - Melanoma | Phase 1 / Phase 2 | Withdrawn | ImmunityBio, Inc. | 2017-12-01 | 2025-02-21 | |
| QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy Avelumab, Bevacizumab, Capecitabine - Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Withdrawn | ImmunityBio, Inc. | 2017-12-01 | 2025-02-24 | |
| QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy avelumab, bevacizumab, capecitabine - Urothelial Carcinoma | Phase 1 / Phase 2 | Withdrawn | ImmunityBio, Inc. | 2017-12-01 | 2025-02-21 | |
| QUILT-3.006 for Recurrent Medullary Thyroid Cancer GI-6207 [Recombinant Saccharomyces cerevisiae-CEA (610D)] - Medullary Thyroid Cancer (MTC) | Phase 2 | Completed | NantCell, Inc. | 35 | 2013-03-26 | 2024-07-09 |
| An Open Label Phase I Study to Eval the Safety and Tolerability of a Vaccine (GI-6207) Consisting of Whole, Heat-killed Recombinant Saccharomyces Cerevisiae (Yeast) Genetically Modified to Express CEA Protein in Adults With Metastatic CEA-expressing ... GI-6207 [Recombinant Saccharomyces Cerevisia, (Yeast CEA Vaccine)(GI-6207[Recombinant Sarrcharomyces Cerevusua-CEA (610D)]) - Prostate Cancer, Breast Cancer | Phase 1 | Completed | National Cancer Institute (NCI) | 25 | 2009-03-13 | 2019-12-12 |
Colorectal Neoplasms (3) · Triple Negative Breast Neoplasms (3) · Pancreatic Neoplasms (2) · Breast Neoplasms (1) · Carcinoma, Medullary (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Squamous Cell (1) · Carcinoma, Transitional Cell (1) · Head and Neck Neoplasms (1) · Lung Neoplasms (1) · Melanoma (1) · Prostatic Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1)
ImmunityBio, Inc. (13) · NantCell, Inc. (1) · National Cancer Institute (NCI) (1)
United States (9)